A Phase 2 interventional study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals, Inc.. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 11th largest by enrollment, is the only one that started in 2007, is one of 2 in phase 2, and was the 7th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2007.
This study's enrollment of 29 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca: 3 open now, 7 under way, 2 of them phase 3. Of 26 finished, 18 (69%) have results posted.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2007, is one of 7 in phase 2, and was the 6th registered.
AstraZeneca’s Hemoglobinuria, Paroxysmal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 35 in Hemoglobinuria, Paroxysmal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.
The objective of this study was to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH. In addition, the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in Japanese patients were assessed and compared to that of non-Japanese patients who had participated earlier studies of eculizumab treatment in hemolytic PNH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
Biological: Eculizumab
Also known as: Soliris
Change From Baseline in Lactate Dehydrogenase
Time frame: Baseline, Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Total Score
The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.
Time frame: Baseline, Week 12
Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Count
Time frame: Baseline, Week 12
Number of Units of Packed Red Blood Cells (pRBCs) Transfused
Comparison of number of units of pRBCs transfused in the 12 weeks prior to the first dose of eculizumab, and between baseline and 12 weeks after the first dose of eculizumab
Time frame: 12 weeks pre-treatment, baseline, 12 weeks post-treatment
Change From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC)
Time frame: Baseline to Week 12
Change From Baseline in Plasma Free Hemoglobin
Time frame: Baseline, Week 12
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status)
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. For global health status, a high score represents a high quality of life.
Time frame: Baseline, Week 12
| Milestone | Eculizumab |
|---|---|
| Started | 29 |
| Completed | 27 |
| Not completed | 2 |
| Withdrew: Lack of efficacy | 2 |
| Units/Liter | Eculizumab |
|---|---|
| Baseline | 1845.1 ± 115.34 |
| Week 12 | 398.7 ± 99.15 |
| Change from Baseline at Week 12 | -1446.4 ± 138.68 |
The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.
| units on a scale | Eculizumab |
|---|---|
| Baseline | 38.5 ± 1.88 |
| Change from Baseline at Week 12 | 4.1 ± 2.25 |
| cells x 10^12/L | Eculizumab |
|---|---|
| Baseline | 1.3 ± 0.14 |
| Week 12 | 1.8 ± 0.19 |
| Change from Baseline at Week 12 | 0.5 ± 0.10 |
Comparison of number of units of pRBCs transfused in the 12 weeks prior to the first dose of eculizumab, and between baseline and 12 weeks after the first dose of eculizumab
| Units | Eculizumab |
|---|---|
| 12 Weeks Pre-Dose | 5.2 ± 1.04 |
| 12 Weeks Post-Dose | 1.5 ± 0.67 |
| Difference Post - Pre | -3.7 ± 1.12 |
| U/L x Day | Eculizumab |
|---|---|
| Change From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC) | -113540.5 ± 10539.33 |
| mg/dL | Eculizumab |
|---|---|
| Baseline | 22.6 ± 2.61 |
| Change from Baseline at Week 12 | -19.8 ± 2.71 |
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. For global health status, a high score represents a high quality of life.
| units on a scale | Eculizumab |
|---|---|
| Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status) | 8.9 ± 6.39 |
Collected over Adverse events were collected over the full study period (12 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 0/29 (0%) | 1/29 (3.4%) | 28/29 (96.6%) |
| Event | Eculizumab |
|---|---|
| PyrexiaGeneral disorders | 1/29 |
| C-Reactive Protein IncreasedInvestigations | 1/29 |
| Event | Eculizumab |
|---|---|
| HeadacheNervous system disorders | 15/29 |
| NasopharyngitisInfections and infestations | 12/29 |
| NauseaGastrointestinal disorders | 6/29 |
| DiarrhoeaGastrointestinal disorders | 4/29 |
| VomitingGastrointestinal disorders | 3/29 |
| EczemaSkin and subcutaneous tissue disorders | 3/29 |
| AnaemiaBlood and lymphatic system disorders | 2/29 |
| LeukopeniaBlood and lymphatic system disorders | 2/29 |
| TinnitisEar and labyrinth disorders | 2/29 |
| Conjunctival haemorrhageEye disorders | 2/29 |
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 47.0 ± 12.39 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 15 |
| Male | 14 |
| Race/Ethnicity, Customized(Participants) | Eculizumab |
|---|---|
| Japanese | 29 |
| Region of Enrollment(Participants) | Eculizumab |
|---|---|
| Japan | 29 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Nov 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 9 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →